Literature DB >> 34216217

The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.

Cedric Tehranian1, Laura Fankhauser1, Patrick N Harter2,3,4, Colin D H Ratcliffe5, Pia S Zeiner2,6,4, Julia M Messmer1,7, Dirk C Hoffmann1,7, Katharina Frey1, Dana Westphal8, Michael W Ronellenfitsch6,4, Erik Sahai5, Wolfgang Wick1,9, Matthia A Karreman1,9, Frank Winkler1,9.   

Abstract

BACKGROUND: Brain metastases (BM) are a frequent complication of malignant melanoma (MM), with limited treatment options and poor survival. Prevention of BM could be more effective and better tolerated than treating established BM in various conditions.
METHODS: To investigate the temporospatial dynamics of PI3K/Akt/mTOR (PAM) pathway activation during BM formation and the preventive potential of its inhibition, in vivo molecular imaging with an Akt biosensor was performed, and long-term intravital multiphoton microscopy through a chronic cranial window in mice.
RESULTS: In vivo molecular imaging revealed invariable PAM pathway activation during the earliest steps of brain colonization. In order to perform a long-term intravascular arrest and to extravasate, circulating MM cells needed to activate their PAM pathway during this process. However, the PAM pathway was quite heterogeneously activated in established human brain metastases, and its inhibition with the brain-penetrant PAM inhibitor GNE-317 resulted in only modest therapeutic effects in mice. In contrast, giving GNE-317 in preventive schedules that included very low doses effectively reduced the growth rate and number of BM in two MM mouse models over time, and led to an overall survival benefit. Longitudinal intravital multiphoton microscopy found that the first, rate-limiting steps of BM formation-permanent intravascular arrest, extravasation, and initial perivascular growth-are most vulnerable to dual PI3K/mTOR inhibition.
CONCLUSION: These findings establish a key role of PAM pathway activation for critical steps of early metastatic brain colonization and reveal its pharmacological inhibition as a potent avenue to prevent the formation of clinically relevant BM.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  PI3K/Akt/mTOR pathway; brain metastasis; dual PI3K/mTOR inhibition; extravasation; tertiary prevention

Mesh:

Substances:

Year:  2022        PMID: 34216217      PMCID: PMC8804893          DOI: 10.1093/neuonc/noab159

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  39 in total

1.  Akt signaling dynamics in individual cells.

Authors:  Sean M Gross; Peter Rotwein
Journal:  J Cell Sci       Date:  2015-06-03       Impact factor: 5.285

2.  Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.

Authors:  Alexandra S Zimmer; Seth M Steinberg; Dee Dee Smart; Mark R Gilbert; Terri S Armstrong; Eric Burton; Nicole Houston; Nadia Biassou; Brunilde Gril; Priscilla K Brastianos; Scott Carter; David Lyden; Stanley Lipkowitz; Patricia S Steeg
Journal:  Future Oncol       Date:  2020-04-09       Impact factor: 3.404

3.  Real-time imaging reveals the single steps of brain metastasis formation.

Authors:  Yvonne Kienast; Louisa von Baumgarten; Martin Fuhrmann; Wolfgang E F Klinkert; Roland Goldbrunner; Jochen Herms; Frank Winkler
Journal:  Nat Med       Date:  2009-12-20       Impact factor: 53.440

4.  Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.

Authors:  Dejan Juric; Filip Janku; Jordi Rodón; Howard A Burris; Ingrid A Mayer; Martin Schuler; Ruth Seggewiss-Bernhardt; Marta Gil-Martin; Mark R Middleton; José Baselga; Douglas Bootle; David Demanse; Lars Blumenstein; Karl Schumacher; Alan Huang; Cornelia Quadt; Hope S Rugo
Journal:  JAMA Oncol       Date:  2019-02-14       Impact factor: 31.777

5.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Fabrice André; Eva Ciruelos; Gabor Rubovszky; Mario Campone; Sibylle Loibl; Hope S Rugo; Hiroji Iwata; Pierfranco Conte; Ingrid A Mayer; Bella Kaufman; Toshinari Yamashita; Yen-Shen Lu; Kenichi Inoue; Masato Takahashi; Zsuzsanna Pápai; Anne-Sophie Longin; David Mills; Celine Wilke; Samit Hirawat; Dejan Juric
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

6.  An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery-the BUMPER study.

Authors:  Teresa Amaral; Heike Niessner; Tobias Sinnberg; Ioannis Thomas; Andreas Meiwes; Claus Garbe; Marlene Garzarolli; Ricarda Rauschenberg; Thomas Eigentler; Friedegund Meier
Journal:  Neurooncol Adv       Date:  2020-10-22

7.  Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.

Authors:  Matthias Osswald; Jonas Blaes; Yunxiang Liao; Gergely Solecki; Miriam Gömmel; Anna S Berghoff; Laurent Salphati; Jeffrey J Wallin; Heidi S Phillips; Wolfgang Wick; Frank Winkler
Journal:  Clin Cancer Res       Date:  2016-08-12       Impact factor: 12.531

8.  Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.

Authors:  Cristina Saura; Johanna Bendell; Guy Jerusalem; Shaun Su; Qinhua Ru; Stefan De Buck; David Mills; Sophie Ruquet; Ana Bosch; Ander Urruticoechea; Joseph T Beck; Emmanuelle Di Tomaso; David W Sternberg; Cristian Massacesi; Samit Hirawat; Luc Dirix; Jose Baselga
Journal:  Clin Cancer Res       Date:  2014-01-27       Impact factor: 12.531

9.  Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

Authors:  H-S Shiah; C-Y Chen; C-Y Dai; C-F Hsiao; Y-J Lin; W-C Su; J-Y Chang; J Whang-Peng; P-W Lin; J-D Huang; L-T Chen
Journal:  Aliment Pharmacol Ther       Date:  2012-11-08       Impact factor: 8.171

10.  Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

Authors:  Sagun Parakh; John J Park; Shehara Mendis; Rajat Rai; Wen Xu; Serigne Lo; Martin Drummond; Catherine Rowe; Annie Wong; Grant McArthur; Andrew Haydon; Miles C Andrews; Jonathan Cebon; Alex Guminski; Richard F Kefford; Georgina V Long; Alexander M Menzies; Oliver Klein; Matteo S Carlino
Journal:  Br J Cancer       Date:  2017-05-18       Impact factor: 7.640

View more
  11 in total

Review 1.  The role of metabolic ecosystem in cancer progression - metabolic plasticity and mTOR hyperactivity in tumor tissues.

Authors:  Anna Sebestyén; Titanilla Dankó; Dániel Sztankovics; Dorottya Moldvai; Regina Raffay; Catherine Cervi; Ildikó Krencz; Viktória Zsiros; András Jeney; Gábor Petővári
Journal:  Cancer Metastasis Rev       Date:  2022-01-14       Impact factor: 9.264

2.  Low and steady wins the race: For melanoma brain metastases, is prevention better than a cure?

Authors:  Agata M Kieliszek; Nikoo Aghaei; Blessing I Bassey-Archibong; Sheila K Singh
Journal:  Neuro Oncol       Date:  2022-02-01       Impact factor: 12.300

Review 3.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 4.  Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.

Authors:  Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2022-10-03       Impact factor: 13.029

Review 5.  Towards updated understanding of brain metastasis.

Authors:  Shuncong Wang; Yuanbo Feng; Lei Chen; Jie Yu; Chantal Van Ongeval; Guy Bormans; Yue Li; Yicheng Ni
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 6.  Mechanisms of Natural Extracts of Andrographis paniculata That Target Lipid-Dependent Cancer Pathways: A View from the Signaling Pathway.

Authors:  Ruth Naomi; Hasnah Bahari; Zhi Yi Ong; Yong Yoke Keong; Hashim Embong; Retnagowri Rajandram; Soo Huat Teoh; Fezah Othman; Rosnani Hasham; Khoo Boon Yin; Priyatharisni Kaniappan; Muhammad Dain Yazid; Zainul Amiruddin Zakaria
Journal:  Int J Mol Sci       Date:  2022-05-26       Impact factor: 6.208

Review 7.  Chloride intracellular channel 1 promotes esophageal squamous cell carcinoma proliferation via mTOR signalling.

Authors:  Huiwu Geng; Cheng Feng; Zhangran Sun; Xu Fan; Yiqing Xie; Jinghua Gu; Libin Fan; Gang Liu; Chao Li; Rick F Thorne; Xu Dong Zhang; Xinying Li; Xiaoying Liu
Journal:  Transl Oncol       Date:  2022-10-14       Impact factor: 4.803

8.  Scutellaria barbata D.Don (SBD) extracts suppressed tumor growth, metastasis and angiogenesis in Prostate cancer via PI3K/Akt pathway.

Authors:  Dongya Sheng; Bei Zhao; Wenjing Zhu; Tiantian Wang; Yu Peng
Journal:  BMC Complement Med Ther       Date:  2022-05-03

9.  DTL Is a Prognostic Biomarker and Promotes Bladder Cancer Progression through Regulating the AKT/mTOR axis.

Authors:  Yongwen Luo; Zhiwen He; Wei Liu; Fenfang Zhou; Tao Liu; Gang Wang
Journal:  Oxid Med Cell Longev       Date:  2022-01-21       Impact factor: 6.543

Review 10.  Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations.

Authors:  Ildiko Krencz; Daniel Sztankovics; Titanilla Danko; Anna Sebestyen; Andras Khoor
Journal:  Cancer Metastasis Rev       Date:  2021-12-27       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.